IBRX
ImmunityBio, Inc.
3.43
USD
This page is just a preview of the data found in TrendSpider’s full version
ImmunityBio, Inc. stock is up 10.29% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 5 PUTs, 5 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 13 Nov 19:36 | 15 Dec, 2023 | 5.00 | 6972 | ||
| 13 Nov 19:57 | 15 Dec, 2023 | 5.00 | 6972 | ||
| 13 Nov 20:30 | 15 Dec, 2023 | 5.00 | 6972 | ||
| 14 Nov 14:47 | 15 Dec, 2023 | 5.00 | 5667 | ||
| 14 Nov 17:30 | 15 Dec, 2023 | 5.00 | 5667 | ||
| 15 Nov 14:42 | 19 Jan, 2024 | 4.00 | 15402 | ||
| 15 Nov 16:02 | 19 Apr, 2024 | 2.50 | 5101 | ||
| 15 Nov 16:04 | 19 Apr, 2024 | 2.50 | 5101 | ||
| 17 Nov 15:42 | 19 Apr, 2024 | 2.50 | 5001 | ||
| 17 Nov 19:30 | 19 Apr, 2024 | 2.50 | 5001 |
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers.
